{'fraction_non_alphanumeric': 0.01689545934530095, 'fraction_numerical': 0.01795142555438226, 'mean_word_length': 5.493150684931507, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preparation and characterization of monoclonal antibodies directed against glycoproteins of bovine leukaemia virus.

Six monoclonal antibodies (MoAbs) directed against glycoproteins of bovine leukaemia virus (BLV) were prepared and characterized. Comparison of these MoAbs with anti-gp51 MoAbs of known epitope specificity by competition antibody binding assay allowed to distinguish two new conformational epitopes C1 and C2 on the molecule of gp51. The epitope C1 is involved in the process of inhibition of formation of syncytia but not in neutralization of VSV/BLV pseudotypes. Three newly prepared MoAbs were directed against known epitopes F, G and H, and their neutralizing activities of biological functions of gp51 were determined. MoAbs BLVgp30-94C11 which was directed against transmembrane glycoprotein gp30 was found not to be involved in neutralization of VSV/BLV pseudotypes and did not inhibit formation of syncytial cells as well.